News and Treatment Updates

Here's where you'll find a regularly updated, broad range of articles written by the AAMDSIF team, allied health organizations and news organizations. By staying well-informed, patients and families are practicing a form of self-support that will help them be more effective self-advocates when engaging with health care providers.

The role of HLA transcription in unrelated hematopoietic cell transplantation

Original Publication Date
Article Source
External Web Content

Abstract Expression levels of HLA are associated with susceptibility to various diseases and outcomes after allogeneic hematopoietic cell transplantation (HCT). However, there has been no comprehensive analysis of the effect of the expression levels of the HLA-A, -B, -C, and…

Pregnancy after hematopoietic stem cell transplant: an international multicenter study

Original Publication Date
Article Source
External Web Content

Key Points A large retrospective study evaluating association between pregnancy after HCT with both conditioning protocols and assisted reproduction. Findings include that some protocols appear more sterilizing than others and the impact of assisted reproduction is substantial…

Clonal Signatures of Telomere Biology Disorders

Original Publication Date
Article Source
External Web Content

Abstract Purpose of Review In inherited bone marrow failure syndromes (IBMFS), clonal hematopoiesis (CH) has been increasingly recognized as a molecular fingerprint of the underlying pathophysiology. A specific clonal profile has been reported in telomere biology disorders (TBDs)…

Gastrin for the treatment of acute graft-versus-host disease of the stomach

Original Publication Date
Article Source
External Web Content

Key Points aGVHD causes loss of gastric stem cells, G-cells, and PCs, leading to increased gastric pH. Pentagastrin therapy repairs stem cell and PC deficits, reverses pH changes, and reduces aGVHD damage, improving survival. Abstract Acute graft-versus-host disease (aGVHD) is a…

CPX-351 (Liposomal Cytarabine and Daunorubicin) versus venetoclax plus hypomethylating agent therapy in newly diagnosed acute myeloid leukemia: a retrospective comparison involving 600 Mayo Clinic patients

Original Publication Date
Article Source
External Web Content

Abstract The comparative value of liposomal cytarabine/daunorubicin (CPX-351) versus venetoclax plus a hypomethylating agent (Ven-HMA) in the frontline treatment of older adults with primary (de novo) or secondary acute myeloid leukemia (AML) remains uncertain. In the current…

Website Feedback

Please use this feedback form to report website issues only. For other issues concerning patients and families, please email help@aamds.org or use the Patient and Family Helpline here.